Aurinia Announces Public Offering of Common Shares VICTORIA, British Columbia--(BUSINESS WIRE)

Announces Public Offering of Common Shares

VICTORIA, British Columbia--(BUSINESS WIRE)--March 13, 2017--Aurinia

Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the

"Company"), a clinical stage biopharmaceutical company focused on the

global immunology market, today announced that it has commenced a

registered underwritten public offering of its common shares (the

Leerink Partners LLC and Cantor Fitzgerald & Co. (collectively, the

"Underwriters") are acting as joint book-running managers for the

Offering. The Company will grant the Underwriters an option exercisable,

in whole or in part, in the sole discretion of the Underwriters, to

purchase additional shares, for a period of up to 30 days.

The offering is subject to market conditions, as well as NASDAQ and TSX

approvals, and there can be no assurance as to whether or when the

offering may be completed, or the actual size or terms of the offering.

For the purposes of the TSX approval, the Company intends to rely on the

exemption set forth in Section 602.1 of the TSX Company Manual, which

provides that the TSX will not apply its standards to certain

transactions involving eligible inter-listed issuers on a recognized

exchange, such as NASDAQ. The Company intends to use the net proceeds of

the Offering for research and development activities, including Phase 3

clinical trial activities for lupus nephritis, and working capital

The Offering is being made pursuant to a U.S. registration statement on

Form F-10, declared effective by the United States Securities and

Exchange Commission (the "SEC") on November 5, 2015 (the "Registration

Statement"), and the Company's existing Canadian short form base shelf

prospectus (the "Base Shelf Prospectus") dated October 16, 2015. The

prospectus supplements relating to the Offering (together with the Base

Shelf Prospectus and the Registration Statement, the "Offering

Documents") will be filed with the securities commissions in the

provinces of British Columbia, Alberta and Ontario in Canada, and with

the SEC in the United States. The Offering Documents will contain

important detailed information about the securities being offered.

Before you invest, you should read the Offering Documents and the other

documents the Company has filed for more complete information about the

Company and the Offering. Copies of the Offering Documents will be

available for free by visiting the Company's profiles on the SEDAR

website maintained by the Canadian Securities Administrators at www.sedar.com

or the SEC's website at www.sec.gov, as applicable.

Alternatively, copies of the prospectus supplement will be available

upon request by contacting Leerink Partners LLC; Attention: Syndicate

Department; One Federal Street; 37th Floor; Boston, MA, 02110, or by

phone at 1-800-808-7525, ext. 6142, or by email at syndicate@leerink.com

or Cantor Fitzgerald & Co., Attn: Capital Markets, 499 Park Ave., 5th

Floor, New York, New York 10022, or by telephone at 212-829-7122, or by

e-mail at prospectus@cantor.com.

This press release does not constitute an offer to sell or the

solicitation of an offer to buy securities, nor will there be any sale

of the securities in any jurisdiction in which such offer, solicitation

or sale would be unlawful prior to the registration or qualification

under the securities laws of any such jurisdiction.

Aurinia is a clinical stage

biopharmaceutical company focused on developing and commercializing

therapies to treat targeted patient populations that are suffering from

serious diseases with a high unmet medical need. The Company is

currently developing voclosporin, an investigational drug, for the

treatment of lupus nephritis (LN). The Company is headquartered in

Victoria, British Columbia and focuses its development efforts globally.

Aurinia Pharmaceuticals Inc.

Head of IR & Communications

Hippolyte, 917-826-2664